An executive order signed by President Trump in May 2025, intended to bring American prescription drug prices in line with those in other developed nations, is unlikely to significantly alter costs for most patients, experts stated. The directive, followed by letters sent to 17 major pharmaceutical manufacturers in July outlining expectations for price reductions, focuses on Medicaid.
According to Luca Maini, an assistant professor of health care policy at Harvard Medical School, the primary beneficiaries of this initiative will be government programs rather than individuals. Most Medicaid beneficiaries already pay minimal out-of-pocket expenses for their medications. Therefore, the "main benefit here is not to the patients using the drugs, but to the fiscal health of the program," Maini explained. State and federal governments are expected to see some financial savings from the policy, which could be particularly welcome amidst budget considerations.
Experts suggest that the impact of this deal on overall drug prices may not be as extensive as the administration has indicated. The focus on Medicaid implies that the broader impact on the general consumer market or insurance costs for the wider population could be limited.